Friday 16 October 2026
Export GLSI’s income statement to Excel — free account
Greenwich LifeSciences, Inc.
GLSI Healthcare Biotechnology
In the quarter to June 2026, EPS grew 10.0% and free cash flow grew 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
14.55
0.77
−5.03%
Follow GLSI
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
0.00 | 0.12 | 0.00 | 27.41 | 70.62 | 51.23 | 23.74 | 1.28 | 1.06 |
Net Debt/EBITDA |
0.00 | 0.05 | 0.00 | 15.41 | 5.92 | 1.68 | 0.75 | 0.23 | 0.32 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.08 | 0.07 | 0.09 | 0.62 | 0.94 | 0.79 | 0.73 | 0.42 | 0.51 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 16.86% | 18.11% | 59.69% | (14.18%) | (16.78%) | (39.08%) | (89.30%) | (457.73%) | (3,068.35%) | |
| (2,320.80%) | (3,114.65%) | (5,067.01%) | (12.98%) | (16.35%) | (38.46%) | (86.87%) | (314.09%) | (376.92%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
282.29% | 262.58% | 249.97% | (6.75%) | (17.04%) | (59.26%) | (132.81%) | (1,920.19%) | (5,480.80%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.22 | 0.74 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.01) | (0.01) | (0.13) | (0.12) | (0.33) | (0.48) | (0.50) | (0.56) | (0.73) |
Cash per Share |
0.00 | 0.01 | 0.00 | 3.02 | 2.10 | 1.04 | 0.54 | 0.31 | 0.46 |
Shareholders Equity per Share |
(0.73) | (0.86) | (0.60) | 2.91 | 2.07 | 1.02 | 0.52 | 0.07 | 0.03 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.73) | (0.86) | (0.60) | 2.91 | 2.07 | 1.02 | 0.52 | 0.07 | 0.03 |
Free Cash Flow |
(0.12) | (0.11) | (0.29) | (1.15) | (4.29) | (6.20) | (6.48) | (7.27) | (9.91) |
Working Capital |
(0.56) | (0.64) | (1.37) | 27.61 | 26.82 | 13.21 | 6.70 | 0.91 | 0.35 |
Net Current Asset Value |
(8.56) | (10.14) | (1.37) | 27.61 | 26.82 | 13.21 | 6.70 | 0.91 | 0.35 |
| Other line items | |||||||||
Quick Ratio |
0.00 | 0.12 | 0.00 | 27.41 | 70.62 | 51.23 | 23.74 | 1.28 | 1.06 |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cash ROIC |
1.42% | 1.15% | 21.83% | (2.05%) | (7.94%) | (23.24%) | (47.32%) | (145.31%) | (151.79%) |
Accounts Payable Turnover |
0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
16,333.75 | 28,145.56 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.01) | (0.01) | (0.13) | (0.12) | (0.33) | (0.48) | (0.50) | (0.56) | (0.73) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
0.22 | 0.22 | 0.50 | 0.72 | 0.47 | 0.22 | 0.24 | 1.53 | 3.84 |
Average Assets |
0.07 | 0.05 | 0.07 | 14.35 | 27.95 | 20.35 | 10.24 | 5.54 | 5.14 |
Average Common Equity |
(9.33) | (9.33) | (5.74) | 13.14 | 27.23 | 20.02 | 9.96 | 3.80 | 0.63 |
Columns are period end dates